Med·Investment | News: Medical Device Investment Events (July 6–19, 2024)

Jiangsu TINGSN Technology Co., Ltd. (hereinafter referred to as "TINGSN") recently announced that the company has successfully completed its Series C financing round. This round of financing was exclusively invested by Jingming Capital. Headquartered in Jiangsu Province, China, TINGSN is a high-tech enterprise specializing in the research and development of cardiac 3D mapping systems.

TINGSN has made remarkable achievements in the field of cardiac electrophysiology, particularly in intracardiac echocardiography technology. The intracardiac echocardiography diagnostic catheter developed by the company, as the first domestically produced product of its kind in China, has successfully obtained market approval from the National Medical Products Administration (NMPA). With its innovation and excellent performance, the product has received high recognition from industry experts.

Intracardiac echocardiography is an important auxiliary method in cardiac surgery, and TINGSN's products can effectively enhance the precision and safety of operations. The company also successfully held a new product launch event for intracardiac echocardiography, jointly envisioning the future of medical imaging technology with industry peers and mapping out a new blueprint for innovative development.

TINGSN Technology has established a strategic partnership for technology research and development with Nanjing University, committing to the continuous innovation of cardiac ultrasound imaging technology. The company's cardiac ultrasound imaging system has successfully completed its first in vivo animal experiment, laying a solid foundation for clinical application and market promotion of the product.

The successful completion of the C-round financing will bring new development opportunities for TINGSN. The company plans to use these funds to accelerate the research and development of new technologies, expand production scale, enhance market competitiveness, and explore both domestic and international markets. TINGSN looks forward to leveraging the power of the capital market through cooperation with Jingming Capital to promote the company’s technological innovation and business growth.

Shanghai UniXelI BIOTECHNOLOGY Co., Ltd. ("UniXelI BIOTECHNOLOGY" for short) recently announced that it has successfully completed a multi-million RMB A+ round of financing. This round of financing was exclusively invested by CAS Venture Capital, with the amount ranking in the top 50% of all A+ rounds of financing this year. Headquartered in Shanghai, China, UniXelI BIOTECHNOLOGY is an innovative pharmaceutical company focused on developing a new generation of cell therapy drugs based on human pluripotent stem cells (hiPSC).

Since its establishment in 2021, UniXelI BIOTECHNOLOGY has built several key technology platforms, including a reprogramming technology platform, a stem cell differentiation platform, the SISBAR lineage tracing technology, and a high-precision gene editing platform. The company’s R&D pipeline focuses on neurodegenerative diseases, aiming to address unmet medical needs, with currently five R&D pipelines in progress.

The R&D team of UniXelI BIOTECHNOLOGY consists of highly qualified scientific researchers, 70% of whom are doctoral executives, demonstrating the company's strong capabilities in the scientific research field. UniXelI BIOTECHNOLOGY covers an area of approximately 4,000 square meters, providing ample space for the company's research and production activities.

Shanghai Bitoo Biotechnology Co., LTD. (hereinafter referred to as "Bitoo Bio") recently announced that the company has successfully completed its Series A financing. This round of financing was exclusively invested by Lingang Blue Bay Capital. Headquartered in Shanghai, China, Bitoo Bio is a high-tech enterprise specializing in the research, development, and manufacturing of PES (polyethersulfone) filters.

Shanghai Bitoo Biotechnology Co.,LTD. is committed to providing high-quality PES filters, which are widely used in various fields such as biopharmaceuticals, food and beverage, chemical industry, and water treatment. PES filters, with their excellent chemical stability, thermal stability, and filtration performance, have become an ideal choice for liquid and gas filtration.

The company's product line covers PES filters of various specifications and accuracies, including microporous membranes, pleated filter cartridges, and capsule filters. The filters from Bitoo Biotechnology ensure high filtration efficiency while also focusing on the safety and reliability of the products, meeting the stringent standards of customers across different industries.

Since its establishment, Bitoo Biotechnology has been committed to providing efficient and precise filtration solutions for the biopharmaceutical industry through technological innovation. The company owns a series of patented technologies, and its products are widely used in key steps such as solid-liquid separation, clarification, concentration, and purification in biopharmaceutical processes. Bitoo Biotechnology's filtration technologies and materials have gained widespread recognition from customers both in China and abroad due to their high retention performance, high flux characteristics, and excellent chemical stability.

Shanghai Bitoo Biotechnology Co., LTD. has an experienced R&D and production team, as well as advanced manufacturing equipment and a strict quality control system. The company continuously engages in technological innovation, focusing on the development of novel filtration materials and technologies to meet the ever-changing demands of the market. The success of this Series A financing round marks a solid step forward for Bitoo Biotechnology in advancing the industrialization of biopharmaceutical filtration technologies and materials. After the completion of the financing, Bitoo Biotechnology will steadily advance the industrialization process of its existing products, accelerate large-scale production, and expedite market promotion. The company plans to speed up talent acquisition, quickly achieve industrial production of new products, and continue to increase investment in technology research and development.

Suzhou Fengzhi Medical Technology Co., Ltd. (hereinafter referred to as "Fengzhi Medical") has recently completed its Pre-A round of financing. This round of financing was exclusively invested by Yuanming Xinzhaoyuan Fund, with Xi Qiao Capital serving as the exclusive financial advisor for this round of financing. The funds will be used for the clinical advancement of Fengzhi Medical's first product, Sperstent® Peripheral Spot Stent, and the ongoing research and development of subsequent innovative pipelines.

Fengzhi Medical, established in September 2022, is a developer of interventional and implantable devices specializing in the peripheral vascular intervention field. The company's core team consists of seasoned experts in vascular intervention, bringing years of industry experience and a commitment to delivering innovative technologies and platform-based solutions to meet the needs of patients and the healthcare market.

The first product of Fengzhi Medical, Sperstent® Peripheral Spot Stent, adopts the company's self-developed coating design and has core advantages such as more precise implantation, simpler operation for doctors, and better vascular patency. The development and clinical progress of this innovative product marks Fengzhi Medical's technical strength and innovation capability in the field of vascular interventional devices.

The success of this Pre-A round of financing has not only provided financial support for FZ Medical, but also injected momentum into its further development in the vascular intervention field. The company plans to use the proceeds from the financing to accelerate the clinical trials and market promotion of the Sperstent® peripheral spot stent, while continuing to increase R&D investment to drive the development of subsequent innovative product pipelines.

Pukang Biotechnology Co., Ltd. (hereinafter referred to as "Pukang Bio") recently announced that the company has successfully secured 100 million RMB in strategic investment from 2345 Network Technology Co., Ltd. The amount of this round of financing ranks in the top 50% of all strategic investments this year, marking that Pukang Bio's R&D strength and market potential in the biopharmaceutical field have been highly recognized by the capital market.

Pukang Biotech, headquartered in Zhejiang Province, China, is a high-tech enterprise specializing in the research and development of live attenuated hepatitis A vaccines. The company is committed to developing safe and effective vaccine products to prevent and control the spread of infectious diseases. Pukang Biotech's R&D team consists of experts in vaccinology, immunology, biotechnology, and clinical medicine, with extensive experience and deep expertise in vaccine development.

The core technologies of the company include virus attenuation technology, cell culture technology, vaccine formulation, and preparation processes. The live attenuated hepatitis A vaccine developed by Procare Bio can effectively stimulate the human immune response and provide long-term and sustained immune protection through advanced attenuation techniques. The successful development of this vaccine will offer a new option for the prevention of hepatitis A, holding significant public health importance.

This strategic investment will provide strong financial support for Pukang Bio's research and development and market promotion. The company plans to use these funds to accelerate the clinical trials and registration applications of the attenuated live vaccine for Hepatitis A, expand the R&D team, strengthen cooperation with scientific research institutions and medical institutions both domestically and internationally, and advance the research and development of other innovative vaccine products.